nach oben

Basic Research in Cardiology

Erschienen in:

01.07.2020 | Original Contribution

Intravenously delivered mesenchymal stem cells prevent microvascular obstruction formation after myocardial ischemia/reperfusion injury

verfasst von: Junzhuo Wang, Ziwei Chen, Qing Dai, Jinxuan Zhao, Zilun Wei, Jiaxin Hu, Xuan Sun, Jun Xie, Biao Xu

Erschienen in: Basic Research in Cardiology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Microvascular obstruction (MVO) after primary percutaneous coronary intervention (pPCI) is identified as an independent risk factor for poor prognosis in patients with acute myocardial infarction (AMI). The inflammatory response induced by ischemia and reperfusion (I/R) injury is considered one of the main mechanisms of MVO. Mesenchymal stem cells (MSCs) are a unique stromal cell type that confers an immunomodulatory effect in cardiac disease. The present study aimed to investigate whether immediate intravenous delivery of MSCs could be used as a potential therapeutic method to attenuate MVO formation. A cardiac catheterization-induced porcine model of myocardial I/R injury was established, and allograft MSCs were immediately delivered intravenously. Cardiac magnetic resonance (CMR) imaging was performed on days 2 and 7 after the operation to determine the infarct area, MVO, and cardiac function. The pigs with allograft MSCs showed decreased MVO and infarct size, as well as an improved left ventricular ejection fraction (LVEF). Histological analysis revealed decreased myocyte area, fibrosis, and inflammatory cell infiltration in the peri-infarct zone of pigs with allograft MSCs. Moreover, the concentrations of interleukin-1β (IL-1β), interleukin-6 (IL-6) and C-reactive protein (CRP) in the serum were reduced in the allograft MSC group compared to the control group. Flow cytometry indicated decreased natural killer (NK) cells in the peripheral blood and ischemic heart tissue in the pigs with allograft MSCs. In summary, allograft MSCs delivered intravenously and immediately after myocardial I/R injury can attenuate MVO formation in a porcine model through a decline in the number of NK cells in the myocardium.

Nur mit Berechtigung zugänglich

Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B (2015) Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res 117:558–575. https://doi.org/10.1161/CIRCRESAHA.114.304792 CrossRefPubMedPubMedCentral

Ansboro S, Roelofs AJ, De Bari C (2017) Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both? Curr Opin Rheumatol 29:201–207. https://doi.org/10.1097/BOR.0000000000000370 CrossRefPubMed

Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J (2003) Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108:863–868. https://doi.org/10.1161/01.CIR.0000084828.50310.6A CrossRefPubMed

Bekkers SC, Yazdani SK, Virmani R, Waltenberger J (2010) Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 55:1649–1660. https://doi.org/10.1016/j.jacc.2009.12.037 CrossRefPubMed

Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay MM, Davie A, Mahrous A, Mordi I, Rauhalammi S, Sattar N, Welsh P, Radjenovic A, Ford I, Oldroyd KG, Berry C (2016) Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging 9:e004148. https://doi.org/10.1161/CIRCIMAGING.115.004148 CrossRefPubMedPubMedCentral

Chullikana A, Majumdar AS, Gottipamula S, Krishnamurthy S, Kumar AS, Prakash VS, Gupta PK (2015) Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17:250–261. https://doi.org/10.1016/j.jcyt.2014.10.009 CrossRefPubMed

De Maria GL, Alkhalil M, Wolfrum M, Fahrni G, Borlotti A, Gaughran L, Dawkins S, Langrish JP, Lucking AJ, Choudhury RP, Porto I, Crea F, Dall'Armellina E, Channon KM, Kharbanda RK, Banning AP (2019) Index of microcirculatory resistance as a tool to characterize microvascular obstruction and to predict infarct size regression in patients with STEMI undergoing primary PCI. JACC Cardiovasc Imaging 12:837–848. https://doi.org/10.1016/j.jcmg.2018.02.018 CrossRefPubMed

Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J (2015) Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation 132:1395–1403. https://doi.org/10.1161/CIRCULATIONAHA.115.017611 CrossRefPubMed

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843. https://doi.org/10.1182/blood.v99.10.3838 CrossRefPubMed

10.

Gyongyosi M, Giurgea GA, Syeda B, Charwat S, Marzluf B, Mascherbauer J, Jakab A, Zimba A, Sarkozy M, Pavo N, Sochor H, Graf S, Lang I, Maurer G, Bergler-Klein J, investigators M (2016) Long-term outcome of combined (percutaneous intramyocardial and intracoronary) application of autologous bone marrow mononuclear cells post myocardial infarction: the 5-year MYSTAR study. PLoS ONE 11:e0164908. https://doi.org/10.1371/journal.pone.0164908 CrossRefPubMedPubMedCentral

11.

Halkos ME, Zhao ZQ, Kerendi F, Wang NP, Jiang R, Schmarkey LS, Martin BJ, Quyyumi AA, Few WL, Kin H, Guyton RA, Vinten-Johansen J (2008) Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol 103:525–536. https://doi.org/10.1007/s00395-008-0741-0 CrossRefPubMed

12.

Hamirani YS, Wong A, Kramer CM, Salerno M (2014) Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging 7:940–952. https://doi.org/10.1016/j.jcmg.2014.06.012 CrossRefPubMedPubMedCentral

13.

Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277–2286. https://doi.org/10.1016/j.jacc.2009.06.055 CrossRefPubMedPubMedCentral

14.

Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, Prasad VK, Kebriaei P, Ringden O (2016) Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol 3:e45–52. https://doi.org/10.1016/S2352-3026(15)00224-0 CrossRefPubMed

15.

Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM (2014) Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311:62–73. https://doi.org/10.1001/jama.2013.282909 CrossRefPubMedPubMedCentral

16.

Heusch G (2016) The coronary circulation as a target of cardioprotection. Circ Res 118:1643–1658. https://doi.org/10.1161/CIRCRESAHA.116.308640 CrossRefPubMed

17.

Heusch G (2019) Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol 114:45. https://doi.org/10.1007/s00395-019-0756-8 CrossRefPubMed

18.

Heusch G, Skyschally A, Kleinbongard P (2018) Coronary microembolization and microvascular dysfunction. Int J Cardiol 258:17–23. https://doi.org/10.1016/j.ijcard.2018.02.010 CrossRefPubMed

19.

Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli-Ducci C, Croisille P, Dall'Armellina E, Dharmakumar R, Eitel I, Fernandez-Jimenez R, Friedrich MG, Garcia-Dorado D, Hausenloy DJ, Kim RJ, Kozerke S, Kramer CM, Salerno M, Sanchez-Gonzalez J, Sanz J, Fuster V (2019) Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. J Am Coll Cardiol 74:238–256. https://doi.org/10.1016/j.jacc.2019.05.024 CrossRefPubMedPubMedCentral

20.

Kaibuchi N, Iwata T, Onizuka S, Yano K, Yamato M, Okano T, Ando T (2017) Cytological character of mini pig mesenchymal stromal cells from various tissues and the attempt of cell sheet formation. Regener Ther 6:83–89. https://doi.org/10.1016/j.reth.2017.02.001 CrossRef

21.

Knorr M, Munzel T, Wenzel P (2014) Interplay of NK cells and monocytes in vascular inflammation and myocardial infarction. Front Physiol 5:295. https://doi.org/10.3389/fphys.2014.00295 CrossRefPubMedPubMedCentral

22.

Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann JF, Marinelli B, Panizzi P, Lee WW, Iwamoto Y, Milstein S, Epstein-Barash H, Cantley W, Wong J, Cortez-Retamozo V, Newton A, Love K, Libby P, Pittet MJ, Swirski FK, Koteliansky V, Langer R, Weissleder R, Anderson DG, Nahrendorf M (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29:1005–1010. https://doi.org/10.1038/nbt.1989 CrossRefPubMedPubMedCentral

23.

Liu W, Xie Y, Gao T, Huang F, Wang L, Ding L, Wang W, Liu S, Dai J, Wang B (2018) Reflection and observation: cell-based screening failing to detect HBV in HUMSCs derived from HBV-infected mothers underscores the importance of more stringent donor eligibility to reduce risk of transmission of infectious diseases for stem cell-based medical products. Stem cell Res Ther 9:177. https://doi.org/10.1186/s13287-018-0920-3 CrossRefPubMedPubMedCentral

24.

Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, Albelda MT, Sikora S, Kharazi A, Vertelov G, Waksman R, Epstein SE (2017) Intravenously delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy. Circ Res 120:1598–1613. https://doi.org/10.1161/CIRCRESAHA.117.310599 CrossRefPubMed

25.

Majmudar MD, Keliher EJ, Heidt T, Leuschner F, Truelove J, Sena BF, Gorbatov R, Iwamoto Y, Dutta P, Wojtkiewicz G, Courties G, Sebas M, Borodovsky A, Fitzgerald K, Nolte MW, Dickneite G, Chen JW, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M (2013) Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 127:2038–2046. https://doi.org/10.1161/CIRCULATIONAHA.112.000116 CrossRefPubMedPubMedCentral

26.

Mayr A, Klug G, Schocke M, Trieb T, Mair J, Pedarnig K, Pachinger O, Jaschke W, Metzler B (2012) Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers. Int J Cardiol 157:391–396. https://doi.org/10.1016/j.ijcard.2010.12.090 CrossRefPubMed

27.

Mu D, Zhang XL, Xie J, Yuan HH, Wang K, Huang W, Li GN, Lu JR, Mao LJ, Wang L, Cheng L, Mai XL, Yang J, Tian CS, Kang LN, Gu R, Zhu B, Xu B (2016) Intracoronary transplantation of mesenchymal stem cells with overexpressed integrin-linked kinase improves cardiac function in porcine myocardial infarction. Sci Rep 6:19155. https://doi.org/10.1038/srep19155 CrossRefPubMedPubMedCentral

28.

Niccoli G, Montone RA, Ibanez B, Thiele H, Crea F, Heusch G, Bulluck H, Hausenloy DJ, Berry C, Stiermaier T, Camici PG, Eitel I (2019) Optimized treatment of ST-elevation myocardial infarction. Circ Res 125:245–258. https://doi.org/10.1161/CIRCRESAHA.119.315344 CrossRefPubMed

29.

Prabhu SD, Frangogiannis NG (2016) The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res 119:91–112. https://doi.org/10.1161/CIRCRESAHA.116.303577 CrossRefPubMedPubMedCentral

30.

Shammaa R, El-Kadiry AE, Abusarah J, Rafei M (2020) Mesenchymal Stem Cells Beyond Regenerative Medicine. Front Cell Dev Biol 8:72. https://doi.org/10.3389/fcell.2020.00072 CrossRefPubMedPubMedCentral

31.

Skyschally A, Haude M, Dorge H, Thielmann M, Duschin A, van de Sand A, Konietzka I, Buchert A, Aker S, Massoudy P, Schulz R, Erbel R, Heusch G (2004) Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation 109:2337–2342. https://doi.org/10.1161/01.CIR.0000127961.66744.F4 CrossRefPubMed

32.

Symons R, Pontone G, Schwitter J, Francone M, Iglesias JF, Barison A, Zalewski J, de Luca L, Degrauwe S, Claus P, Guglielmo M, Nessler J, Carbone I, Ferro G, Durak M, Magistrelli P, Lo Presti A, Aquaro GD, Eeckhout E, Roguelov C, Andreini D, Vogt P, Guaricci AI, Mushtaq S, Lorenzoni V, Muller O, Desmet W, Agati L, Janssens S, Bogaert J, Masci PG (2018) Long-term incremental prognostic value of cardiovascular magnetic resonance after st-segment elevation myocardial infarction: a study of the collaborative registry on CMR in STEMI. JACC Cardiovasc Imag 11:813–825. https://doi.org/10.1016/j.jcmg.2017.05.023 CrossRef

33.

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497–2505. https://doi.org/10.1056/NEJMoa1912388 CrossRefPubMed

34.

Traverse JH, Swingen CM, Henry TD, Fox J, Wang YL, Chavez IJ, Lips DL, Lesser JR, Pedersen WR, Burke NM, Pai A, Lindberg JL, Garberich RF (2019) NHLBI-sponsored randomized trial of postconditioning during primary percutaneous coronary intervention for ST-elevation myocardial infarction. Circ Res 124:769–778. https://doi.org/10.1161/CIRCRESAHA.118.314060 CrossRefPubMedPubMedCentral

35.

van den Akker F, de Jager SC, Sluijter JP (2013) Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. Mediat Inflamm 2013:181020. https://doi.org/10.1155/2013/181020 CrossRef

36.

van den Akker F, Deddens JC, Doevendans PA, Sluijter JP (2013) Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochem Biophys Acta 1830:2449–2458. https://doi.org/10.1016/j.bbagen.2012.08.026 CrossRefPubMed

37.

Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, Hu X, Jiang S, Shi S, Sun L (2014) Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 16:R79. https://doi.org/10.1186/ar4520 CrossRefPubMedPubMedCentral

38.

Zhao J, Li X, Hu J, Chen F, Qiao S, Sun X, Gao L, Xie J, Xu B (2019) Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res 115:1205–1216. https://doi.org/10.1093/cvr/cvz040 CrossRefPubMedPubMedCentral

39.

Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu Q, Xu J (2018) Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res 374:1–15. https://doi.org/10.1007/s00441-018-2871-5 CrossRefPubMed

Titel: Intravenously delivered mesenchymal stem cells prevent microvascular obstruction formation after myocardial ischemia/reperfusion injury
verfasst von: Junzhuo Wang
Ziwei Chen
Qing Dai
Jinxuan Zhao
Zilun Wei
Jiaxin Hu
Xuan Sun
Jun Xie
Biao Xu
Publikationsdatum: 01.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Basic Research in Cardiology / Ausgabe 4/2020
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-020-0800-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Intravenously delivered mesenchymal stem cells prevent microvascular obstruction formation after myocardial ischemia/reperfusion injury

Abstract

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Remote ischemic preconditioning reduces myocardial ischemia–reperfusion injury through unacylated ghrelin-induced activation of the JAK/STAT pathway

Inflammation shapes pathogenesis of murine arrhythmogenic cardiomyopathy

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

Vascular autophagy in health and disease

Nuclear localization of a novel calpain-2 mediated junctophilin-2 C-terminal cleavage peptide promotes cardiomyocyte remodeling

Deficiency of Nucleotide-binding oligomerization domain-containing proteins (NOD) 1 and 2 reduces atherosclerosis

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie